FDA Approved: MYLOTARG — Original Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)

View source ↗

Summary

FDA approval of Mylotarg (gemtuzumab ozogamicin) under the original application from Wyeth/Pfizer for treatment of acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Mylotarg (gemtuzumab ozogamicin)

Snippet

ORIG AP for MYLOTARG (GEMTUZUMAB OZOGAMICIN)